Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | PSMA-targeted alpha emitter 225Ac-J591 for mCRPC

Scott Tagawa • 22 May 2020
ASCO 2020
Genitourinary Cancer Prostate Cancer 225Ac-J591

Scott Tagawa, MD, MS, FACP, Weill Cornell Medicine, New York, NY, USA, discusses a Phase I dose-escalation study (NCT03276572) of the PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Scott Tagawa

1:41
PSMAddition: 177Lu-PSMA-617 plus standard of care vs SoC alone in patients with mHSPC
Scott Tagawa • 3 Jun 2023
2:57
Efficacy of sacituzumab govitecan in mUC by Trop-2 expression
Scott Tagawa • 3 Jun 2023
1:51
Future directions in the field of targeted therapies for urothelial carcinoma
Scott Tagawa • 3 Jun 2023
3:07
PSMA-TRT, 225Ac-J591 and 177Lu-PSMA I&T in mCRPC
Scott Tagawa • 3 Jun 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals